Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).

As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Atkore Inc (ATKR) Tops Q3 EPS by 14c
• Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS
• Regency Centers (REG) Tops Q2 EPS by 2c